Abstracts Archive - Page 1961 of 2425 - ACR Meeting Abstracts

Abstract Number: 1362 • 2014 ACR/ARHP Annual Meeting
Impact of Rapid Attainment of Stringent Measures of Efficacy in Rheumatoid Arthritis on Patient-Reported Outcomes
EA Alemao¹, S Joo², S Banerjee¹, P Emery³ and M Weinblatt⁴, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³University of Leeds, Leeds, United Kingdom, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Treatment guidelines in RA recommend that therapies aim to reach a target of remission or low disease activity (LDA) and that these targets should…
Abstract Number: 1381 • 2014 ACR/ARHP Annual Meeting
Subaxial Cervical Spine Involvement in Symptomatic Rheumatoid Arthritis Patients: Comparison with Cervical Spondylosis
Helena Borrell¹, Javier Narváez², Jose Antonio Narvaez³, Marta Serrallonga⁴, Carmen Gomez Vaquero¹, Eugenia de Lama⁵, Javier Hernandez Gañan³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Radiology Department, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁴Institut de Diagnostic per la Imatge (IDI), Centre Bellvitge, Barcelona, Spain, ⁵Radiology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To investigate the frequency, location, nature, and clinical significance of subaxial involvement (below C1-C2) in a series of patients with rheumatoid arthritis (RA) and…
Abstract Number: 1374 • 2014 ACR/ARHP Annual Meeting
A Comparison of the Risk for Cardiovascular Event in Patients with Rheumatoid Arthritis Treated with Biologic Disease Modifiers and Patients Treated with Methotrexate Only
Majed Khraishi¹ and Rana Aslanov², ¹Nexus Clinical Research, St John's, NF, Canada, ²Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada
Background/Purpose We aimed to investigate whether the 10-year cardiovascular risk (CV) differs between patients with RA treated with Biologic Disease Modifiers (BDMARDs) and Methotrexate (MTX)…
Abstract Number: 1357 • 2014 ACR/ARHP Annual Meeting
Improving Compliance for Tuberculosis Screening for Patients on Biologics in Rheumatology Clinics
Shraddha Jatwani¹, Rajani Rudrangi¹, Karan Jatwani², Vijaya Murthy¹, Rashmi Maganti¹, Rex McCallum¹ and Emilio Gonzalez¹, ¹Rheumatology, University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, Galveston, TX
Background/Purpose: Biologics are used commonly for patient with autoimmune diseases. These agents have ensured important efficacy advantages in the treatment of inflammatory rheumatic diseases. All…
Abstract Number: 1356 • 2014 ACR/ARHP Annual Meeting
Collaboration Between a Third Party Payer and Community Rheumatologists to Create a Clinical Pathway for the Treatment of Rheumatoid Arthritis to Assure Proper Use of Biologics and Quality of Care
Alan K. Matsumoto¹, Herbert S. B. Baraf², Bruce Feinberg³, Phil Miller⁴ and Daniel Winn⁴, ¹Rheumatology, Arthritis & Rheumatism Associates, PC, Wheaton, MD, ²Arthritis & Rheumatism Associates, PC, Wheaton, MD, ³Cardinal Health, Dublin, OH, ⁴CareFirst BlueCross, Baltimore, MD
Background/Purpose Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…
Abstract Number: 1355 • 2014 ACR/ARHP Annual Meeting
Population Management of Rheumatoid Arthritis (RA) in Rheumatology Practices: A Quality Improvement Project
David Sikes¹, Gary Crump², Kathleen Thomas³, Alex Bangs⁴ and J. Timothy Harrington⁵, ¹Rheumatology, Florida Medical Clinic PA, Zephyrhills, FL, ²Rheumatology Associates - Louisville, Louisville, KY, ³Community Rheumatology, Noblesville, IN, ⁴Crescendo Bioscience, Inc, South San Francisco, CA, ⁵Joiner Associates LLC, Madison, WI
Background/Purpose: Population management (PM) is required for reducing the burdens of chronic diseases, including RA. PM depends on standardizing disease activity assessment (DAA) and coordinating…
Abstract Number: 1354 • 2014 ACR/ARHP Annual Meeting
Improving the Measurement of Disease Activity for Patients with Rheumatoid Arthritis: Validation of an Electronic Version of the Routine Assessment of Patient Index Data (RAPID 3)
Ruthie May Chua¹, John Mecchella^2,3 and Alicia Zbehlik^4,5, ¹Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ⁵The Geisel School of Medicine at Dartmouth, The Dartmouth Centers for Health and Aging, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH
Background/Purpose Quantitative measures of disease activity are associated with improved outcomes for patients with rheumatoid arthritis (RA), but many rheumatologists continue to rely on non-quantitative…
Abstract Number: 1353 • 2014 ACR/ARHP Annual Meeting
Integrating Collection of Rheumatoid Arthritis Disease Activity and Physical Function Scores into an Academic Rheumatology Practice to Improve Quality of Care
Vladimir Chernitskiy¹, Andre DeVito², Naama Neeman², Niraj Sehgal², Jinoos Yazdany³ and Andrew J. Gross³, ¹Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: The default design of our institutions’ electronic health record (EHR)(Epic Systems) was not optimally structured to systematically collect quality metrics for rheumatic disease management…
Abstract Number: 1352 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Disease Activity Assessment and Population Management Processes Used By Clinician Rheumatologists
Anne Winkler¹, James Mossell², Edmund MacLaughlin³, Drew Johnson⁴ and J. Timothy Harrington⁵, ¹Rheumatology, Winkler Medical Practice LLC, Springfield, MO, ²Arthritis & Osteo Center of South GA, Tifton, GA, ³Edmund L. MacLaughlin LLC, Cambridge, MD, ⁴Crescendo Bioscience, Inc., South San Francisco, CA, ⁵Joiner Associates LLC, Madison, WI
Background/Purpose: Timely disease activity assessment (DAA) and population management (PM) are known to reduce the burdens of chronic diseases, including RA. Currently, the measures and…
Abstract Number: 1351 • 2014 ACR/ARHP Annual Meeting
Assessment of ACR Endorsed Quality Indicators in Rheumatoid Arthritis Patients – a Quality Improvement Initiative
Puneet Bajaj¹, Erik Anderson², Siddharth Raghavan², Asha Patnaik¹ and Heidi Roppelt¹, ¹Rheumatology, Stony Brook University Medical Center, East Setauket, NY, ²Internal Medicine, Stony Brook University Medical Center, East Setauket, NY
Background/Purpose: Quality assessments are being increasingly used for quality improvement, accountability, and performance based incentives. The current research regarding quality of care provided to rheumatoid…
Abstract Number: 1350 • 2014 ACR/ARHP Annual Meeting
Practice What You Preach? Suboptimal Guideline Adherence By Rheumatologists in Patients with Rheumatoid Arthritis
Nienke Lesuis¹, Ronald van Vollenhoven², Marlies Hulscher³ and Alfons den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³IQ Healthcare, Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Tight control based treatment principles of rheumatoid arthritis (RA) are superior to usual care and therefore recommended in many (inter)national guidelines.1-3 Unfortunately guideline adherence…
Abstract Number: 1349 • 2014 ACR/ARHP Annual Meeting
A Decision Support Tool to Improve Herpes Zoster Vaccination Rates Among Patients Starting Biologic Medications
Sara Schoenfeld¹, Eli Miloslavsky¹, Weihong Yang¹, Naina Rastalsky¹, Mollie Carruthers¹, Zachary Wallace¹, Traci Powers¹, Marcy Bolster² and Deborah Collier¹, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital / Harvard Medical School, Boston, MA
Background/Purpose Herpes zoster infection causes serious morbidity and mortality in immunocompromised patients. Vaccination reduces the risk of zoster infection by up to 40% among patients…
Abstract Number: 1348 • 2014 ACR/ARHP Annual Meeting
Improvement in Herpes Zoster Vaccination and Documentation for Rheumatoid Arthritis Patients Using Electronic Medical Record
Heena Sheth¹, Siamak Moghadam-Kia¹, Rayford June², Hilary J. Peterson¹, Davi Sa Leitao³, Larry W. Moreland⁴ and Rohit Aggarwal¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Despite increased risk of herpes zoster (HZ) in rheumatoid arthritis (RA) patients on immunosuppressive medication, American College of Rheumatology guidelines on HZ vaccination in…
Abstract Number: 1347 • 2014 ACR/ARHP Annual Meeting
Understanding Vaccination Rates Among Patients with Rheumatoid Arthritis
Diana S Sandler¹, Eric M. Ruderman², Tiffany Brown³, Ji Young Lee³, Amanda Ozanich³, David T Liss³ and David W Baker³, ¹Medicine/Rheumatology, Northwestern University, Chicago, IL, ²Div of Rheumatology, Northwestern University, Chicago, IL, ³Northwestern University, Chicago, IL
Background/Purpose: Vaccinations are important for patients with rheumatoid arthritis (RA) who may receive immunosuppressive therapies that increase their risk of infection. The Advisory Committee on…
Abstract Number: 1346 • 2014 ACR/ARHP Annual Meeting
Leveraging Electronic Health Records to Improve Vaccination Rates for Patients with Rheumatoid Arthritis
David W Baker¹, Tiffany Brown¹, Ji Young Lee¹, Diana S Sandler², David T Liss¹, Amanda Ozanich¹, Elizabeth Harsha Strong³, Alpa Patel¹ and Eric M. Ruderman⁴, ¹Northwestern University, Chicago, IL, ²Medicine/Rheumatology, Northwestern University, Chicago, IL, ³Rheumatology, Northwestern University, Chicago, IL, ⁴Div of Rheumatology, Northwestern University, Chicago, IL
Background/Purpose: Vaccination rates among patients with rheumatoid arthritis (RA) remain low. Improving these rates is important, as RA patients are inherently immunocompromised and frequently treated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].